Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:33:08 EDT Sat 18 May 2024
Enter Symbol
or Name
USA
CA



Z:ATNM - ACTINIUM PHARMACEUTICALS INC - http://www.actiniumpharmaceuticals.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ATNM - Z0.18.88·9.730.49.80-0.0768-0.8203.81,8531,5039.84  9.95  9.4610.24  4.0018:34:57May 1515 min RT 2¢

Recent Trades - Last 10 of 1503
Time ETExPriceChangeVolume
18:34:57Z9.73-0.1220
18:24:37Z9.73-0.1240
18:24:34Z9.73-0.12100
18:24:34Z9.73-0.1220
18:18:40Z9.73-0.12200
18:18:40Z9.73-0.1250
17:41:42Z9.73-0.121
17:37:00Z9.73-0.125
16:31:54Z9.73-0.123
16:26:40Z9.73-0.121

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-15 08:30U:ATNMNews ReleaseActinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity
2024-05-14 18:38U:ATNMNews ReleaseActinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Pha
2024-05-13 08:30U:ATNMNews ReleaseActinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
2024-05-07 08:00U:ATNMNews ReleaseActinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern
2024-04-18 08:00U:ATNMNews ReleaseActinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
2024-04-01 08:00U:ATNMNews ReleaseActinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annua
2024-03-26 07:18U:ATNMNews ReleaseActinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
2024-03-11 07:30U:ATNMNews ReleaseActinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
2024-02-26 07:30U:ATNMNews ReleaseActinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT(TM) and CI
2024-02-23 07:30U:ATNMNews ReleaseActinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT(TM) and
2024-01-02 07:30U:ATNMNews ReleaseActinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT ‚ ® and CIBMTR ‚ ®
2023-12-11 08:15U:ATNMNews ReleaseActinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation
2023-12-11 07:45U:ATNMNews ReleaseActinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia
2023-12-08 08:00U:ATNMNews ReleaseActinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
2023-11-06 07:30U:ATNMNews ReleaseActinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations
2023-11-02 16:15U:ATNMNews ReleaseActinium Pharmaceuticals to Attend Bio-Europe Munich 2023
2023-11-02 09:05U:ATNMNews ReleaseActinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial
2023-10-04 07:30U:ATNMNews ReleaseActinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy
2023-09-27 09:05U:ATNMNews ReleaseActinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual Meeting
2023-09-07 08:40U:ATNMNews ReleaseActinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO